Neoadjuvant systemic therapy of HER2-positive breast cancer
| Autor: | M A Frolova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Современная онкология, Vol 17, Iss 4, Pp 22-25 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1815-1434 1815-1442 |
| Popis: | HER2 overexpression is evaluated in 15-20% of breast tumors and associated with aggressive type of the disease. Introduction of trastuzumab in clinical practice significantly improve the prognosis of patients with metastatic and early HER2-positive breast cancer. However, up to 40% of patients have a resistance to trastuzumab therapy (de novo or acquired resistance). Dual anti-HER2 blockade of trastuzumab in combination with other anti-HER2 targeted agents is more effective then trastuzumab monotherapy. Neoadjuvant systemic therapy has become very useful in early breast cancer and serves as a model for research of new antitumor agents, treatment regimens and predictive biomarkers. In current review the most important recent neoadjuvant trials in HER2-positive breast cancer and their impact on clinical practice are being analysed. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|